Dr. Amar N. Rewari, MBA, MD

Dr. Rewari practices at Luminis Health Anne Arundel Medical Center in Annapolis, Maryland, part of Luminis Health.

Dr. Rewari's NPI, 1336458942, was assigned on September 30, 2010. Dr. Rewari graduated from Yale University School of Medicine in 2006. Dr. Rewari holds Maryland license D74705.

Dr. Rewari's primary practice is Luminis Health Anne Arundel Medical Center, at 2001 Medical Parkway, Annapolis, MD 21401 in Anne Arundel County. The practice phone is (443) 481-1000.

Dr. Rewari's primary practice is Luminis Health Anne Arundel Medical Center in Annapolis, Maryland, part of Luminis Health. Dr. Rewari is also affiliated with The Johns Hopkins Hospital. The medical group on file is Luminis Health Maternal and Fetal Medicine Annapolis. Dmand AI also links Dr. Rewari to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rewari practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rewari's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Rewari is licensed in Maryland.

CMS data shows 3,047 Medicare services from Dr. Rewari across 16 procedure codes in 2024, for 137 Medicare patients. Medicare paid $189,306 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 137 Medicare patients who saw Dr. Rewari in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rewari's median patient age at 73, with 39% women.

In 2024, Dr. Rewari wrote 103 Medicare Part D claims for 39 patients. 89% of them were for generic drugs. CMS names the drug for 32 of them, across 1 drug with 11 or more claims each, at $325 in total drug cost. In 2023, CMS named 49 claims across 2 drugs.

Dr. Rewari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rewari as offering telehealth.

Dmand AI links 6 papers to Dr. Rewari, published from 2012 to 2023. The most frequent topics are COVID-19, Radiation Oncology and Radiotherapy, Adjuvant. Dr. Rewari has published most often in Int J Radiat Oncol Biol Phys. Dr. Rewari's most frequent co-authors are Manjeet J. Chadha, MD, Parima Daroui, MD, PhD and Karen Kim Evans, MD.

Dmand AI links Dr. Rewari to 2 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Small Cell Lung Carcinoma and Carcinoma, Bronchogenic.

CMS Open Payments shows 20 general payments to Dr. Rewari from 16 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Novocure Inc. paid the most, $136.

Dr. Rewari graduated from Yale University School of Medicine in 2006.